Feasibility of Umbilical Cord Blood Collection in Neonates at Risk of Brain Damage—A Step Toward Autologous Cell Therapy for a High-risk Population

Angela Segler1, Thorsten Braun1,2, Hendrik Stefan Fischer3, Ricarda Dukatz1, Claire-Rachel Weiss1, Alexander Schwickert1, Carsten Jäger4, Christoph Bührer3, and Wolfgang Henrich1

Abstract
Evidence for umbilical cord blood (UCB) cell therapies as a potential intervention for neurological diseases is emerging. To date, most existing trials worked with allogenic cells, as the collection of autologous UCB from high-risk patients is challenging. In obstetric emergencies the collection cannot be planned. In preterm infants, late cord clamping and anatomic conditions may reduce the availability. The aim of the present study was to assess the feasibility of UCB collection in neonates at increased risk of brain damage. Infants from four high-risk groups were included: newborns with perinatal hypoxemia, gestational age (GA) ≤30 + 0 weeks and/or birthweight <1,500 g, intrauterine growth restriction (IUGR), or monochorionic twins with twin-to-twin transfusion syndrome (TTTS). Feasibility of collection, quantity and quality of obtained UCB [total nucleated cell count (TNC), volume, sterility, and cell viability], and neonatal outcome were assessed. UCB collection was successful in 141 of 177 enrolled patients (hypoxemia n = 10; GA ≤30 + 0 weeks n = 54; IUGR n = 71; TTTS n = 6). Twenty-six cases were missed. The amount of missed cases per month declined over the time. Volume of collected UCB ranged widely (median: 24.5 ml, range: 5.0–102 ml) and contained a median of 0.77 × 10^8 TNC (range: 0.01–13.0 × 10^8). TNC and UCB volume correlated significantly with GA. A total of 10.7% (19/177) of included neonates developed brain lesions. To conclude, collection of UCB in neonates at high risk of brain damage is feasible with a multidisciplinary approach and intensive training. High prevalence of brain damage makes UCB collection worthwhile. Collected autologous UCB from mature neonates harbors a sufficient cell count for potential therapy. However, quality and quantity of obtained UCB are critical for potential therapy in preterm infants. Therefore, for extremely preterm infants alternative cell sources such as UCB tissue should be investigated for autologous treatment options because of the low yield of UCB.

Keywords
umbilical cord blood (UCB), collection of UCB, autologous UCB, perinatal brain damage, preterm infants, perinatal hypoxemia

1 Department of Obstetrics, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
2 Department of “Experimental Obstetrics” and Study group “Perinatal Programming”, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
3 Department of Neonatology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
4 Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

Submitted: May 03, 2020. Revised: December 30, 2020. Accepted: January 14, 2021.

Corresponding Author:
Angela Segler, Department of Obstetrics, Charité – Universitätsmedizin Berlin, Augustenburgerplatz 1, 13353 Berlin, Germany.
Email: Angela.segler@charite.de
Introduction

Impressive advances in perinatal and neonatal care have led to substantial improvements in survival rates for preterm infants and neonates with severe complications. However, survival comes at a cost. Neonates with brain damage often suffer from long-term neurological motor and cognitive deficits resulting in enormous physical, psychological, and economic costs. Cerebral palsy (CP) is one of the most costly neurologic disabilities due to its frequency (2/1,000 births) and persistence over life. Currently available treatments for patients with CP are supportive, but not curative. Apart from term infants with perinatal hypoxemia, preterm infants, monochorionic twins with twin-twin transfusion syndrome (TTTS), and infants with intrauterine growth restriction (IUGR) are also frequently affected by cerebral damage. Up to 10% of very low birthweight infants (<1,500 g) suffer from CP and 16% of very preterm infants (22 to 28 weeks) are complicated with severe intraventricular hemorrhage (IVH). TTTS is a rare but severe complication that can result in death of a co-twin and leaves up to 30% of survivors with an abnormal neurodevelopment.

A new approach for neonates with brain damage is the treatment with umbilical cord blood (UCB) derived cells. UCB contains a large amount of highly proliferative progenitor cells and stem cells. Bystander effects have been postulated to be the main mechanisms for functional recovery after cord blood transplantation. Transplanted UCB cells may migrate to the affected area and deliver trophic factors that provide anti-inflammatory and antiapoptotic effects and increase the plasticity of the injured brain by enhancing neovascularization, myelination, and endogenous neurogenesis. In several animal models, neurological and survival benefits have been demonstrated for the application of UCB cells in the setting of stroke, ischemia, intracranial hemorrhage, and spinal cord injury. Current pilot studies suggested benefits of autologous cell treatments in term infants with hypoxic-ischemic (HIE) and CP. Autologous approaches harbor a minimal risk of immunogenic reaction and infections compared to allogenic approaches.

Nevertheless, current clinical trials mostly work with allogeneic UCB cells. This is mostly due to the logistic advantage of allogeneic approaches. Allogeneic cell products can be manufactured and be used “off the shelf” in the clinical setting. The collection of autologous cells is more complicated and the quality of the resulting cell products is directly depending on the quality of the individual collection sample making it difficult to compare. In order to design valuable clinical trials, the preparation of cells from individual cell sources has to become standardized. Trials directly comparing autologous and allogeneic treatment options in neonates are lacking. Those working with autologous UCB cells mostly involve mature neonates or preterm infants with a minimum of 28 + 1 to 37 + 0 weeks of gestation.

It is unclear whether autologous UCB collection is feasible for the aforementioned high-risk populations. In very preterm infants (<30 + 0 weeks of gestations), late cord clamping and anatomic conditions limit the available amount of UCB. In emergency situations or unexpected deliveries, the collection cannot be planned. Thus, collection of UCB requires a good collaboration especially in large perinatal centers with constantly changing teams of clinicians and midwives. The aim of the present study is to investigate the feasibility of autologous UCB collection in high-risk neonatological populations and to assess the quantity and quality of the samples collected. The successful collection of UCB in challenging anatomical conditions and emergency situations is essential prerequisite to allow for autologous treatment options.

Methods

Study Design

We initiated this pilot study in December 2017. This study was approved by the Institutional Ethics Committee of the Charité – Universitätsmedizin Berlin (Berlin, Germany) (EA2/206/17). The use of human UCB and all procedures in this study were conducted in accordance with the Institutional Ethics Committee of the Charité – Universitätsmedizin Berlin (Berlin, Germany) (EA2/206/17) approved protocols. Written informed consent was obtained from the patients for their anonymized information to be published in this article. The project was designed in collaboration with Vita 34 AG (Leipzig, Germany), a European cord blood bank, in order to use the established infrastructure and guarantee high standards for the banking of the acquired cord blood. To enhance dedication and compliance with the project, team briefings for all obstetricians, midwives, and anesthetists were held discussing the current state of literature on UCB therapy in neonates and the aim of the study.

All midwives and obstetricians were trained for collection of UCB. Candidates for UCB collection were infants from four high-risk groups: perinatal symptomatic hypoxemia, extremely preterm infants (gestational age 23 + 0 to 30 + 0 weeks and/or estimated birthweight less than 1,500 g), estimated IUGR <3rd percentile for gestational age, and monochorionic twins with TTTS. After emergency C-sections or other obstetrical emergency situations, UCB was always collected. Neonates were included in the study, if criteria for any of the four groups were met or if criteria for therapeutic hypothermia were met (defined as metabolic or mixed acidosis with an arterial cord pH ≤7.0 or a base deficit of >16 or an Apgar score at 10 min of ≤5 or need for positive pressure ventilation for ≥10 min). If the neonate did not meet the inclusion criteria, the UCB was discarded. Neonates with mothers positive for hepatitis B (HBsAg and/or HBcAg) or C virus (anti-HCV), syphilis, HIV (anti-HIV-1 and -2) cytomegalovirus (IgM antibodies), rubella, toxoplasma, or
herpes simplex virus were excluded as were mothers under the age of 18. UCB collection was performed aseptically via in utero or ex utero techniques into cord blood collection bags (Vita 34 AG) containing 35 ml of citrate phosphate dextrose anticoagulant. Mothers who were at high risk for preterm delivery, expecting an IUGR child, or multiples with TTTS were informed about the study and prior written informed consent for collection was sought if admitted to the hospital (see Fig. 1). For deliveries in which prior collection consent had not been obtained, the local Ethics committee gave permission for obstetric staff to collect UCB and seek the mothers consent after delivery. If UCB was successfully collected and the infant met the inclusion criteria, mothers were asked to provide written informed consent for study participation. If she did not consent the blood was discarded.

Assessment of UCB Quantity and Quality

The obtained UCB was transported at room temperature in a validated transport box to Vita 34 AG cord blood bank and processed, cryopreserved, and banked according to the manufacturing authorization for cord blood transplants of Vita 34. The whole blood was cryopreserved in a rate-controlled freezer with the cryoprotectant dimethylsulfoxide. The UCB was stored in the vapor phase above liquid nitrogen at temperature between −150°C and −185°C. The UCB was banked at Vita 34 for the affected families free of charge in order to be available for future therapeutic options. Total nucleated cell count (TNC) pre- and post-processing, sterility, and viability were assessed by microscopic counting, by anaerobic and aerobic BACTEC blood culture system (Becton Dickinson, Franklin Lakes, NJ, USA) and by acridine orange staining, respectively. In cases of missed UCB collection circumstances leading to failure were assessed. Missed cases were discussed on daily ward rounds.

Assessment of Neonatal Outcome

Neonatological outcome was assessed through medical charts and radiology reports. All neonates received treatment and diagnostic tests according to standard operating procedures of the hospital, including cranial ultrasound, magnetic resonance imaging, and amplitude-integrated electroencephalograms, as applicable. HIE was defined as perinatal asphyxia accompanied by pathological amplitude-integrated electroencephalogram, seizures, or other neurological symptoms and signs. CP was diagnosed based on

**Figure 1.** Distribution of cases. The flow chart is describing the process of case inclusion and assessment of feasibility and UCB quality/quantity. UCB: umbilical cord blood.
clinical assessment and radiological findings. For the assessment of IVH, cranial ultrasound scans were graded according to the Papile scoring system. Periventricular leukomalacia (PVL) was defined as cystic PVL and diagnosed by neuroimaging using cranial ultrasound.

Statistical Analyses

We used descriptive statistics to characterize subject demographics and feasibility measures. Continuous variables are reported as median and range. Categorical variables are summarized as frequency counts and percentages. The correlations between gestational age and the quantity and quality measures of the UCB specimens were investigated using Spearman’s rank correlation test, as appropriate. A significance level of 0.05 (P value) was determined for all calculations. All statistical analyses were performed using IBM SPSS, v22 for Windows (IBM Inc., Armonk, NY, USA).

Results

Distribution of Cases

The distribution of cases is further summarized in Fig. 1. Between 12/2017 and 12/2018, UCB was collected from two groups: first, unexpected obstetric emergencies (n = 101) and second from patients with expected high-risk deliveries (n = 110), that had given their consent prior to inclusion. Five patients refused written consent prior to inclusion and were excluded from the study. In the first group of obstetric emergencies, UCB collection was attempted in most cases (75.2%, 76/101). UCB collected from 21 neonates in initially critical clinical condition (shoulder dystocia n = 2, placental abruption n = 3, uterine rupture n = 2, prolapse of the arm n = 2, and terminal bradycardia n = 12) and was later discarded for not meeting the inclusion criteria of symptomatic hypoxemia. Two patients refused written consent after successful collection of UCB and the collected UCB was also discarded. In the second group of expected high-risk deliveries, an even higher percentage of collections was attempted (89.1%, 98/110).

In 17.5% (37/211) of all cases the collection of UCB was missed due to organizational difficulties (obstetric emergencies n = 25, expected high-risk delivery n = 12). Of those cases 13.5% (5/37) were spontaneous deliveries, 16.2% (6/37) vacuum extractions, 18.9% (7/37) elective C-sections, and 51.4% (19/37) crash/emergency C-sections. However, only 14.6% (26/177) of the cases with fulfilled inclusion criteria were missed, including 7 cases of perinatal hypoxemia, 10 with a gestational age ≤ 30 + 0 weeks, and 9 children with IUGR.

In a small number of cases (5.6%, 10/177) the collection was attempted but failed in a clinical setting of placental abruptions, uterine ruptures, transplacental deliveries, and neonates with a gestational age of less than 24 + 0 weeks. UCB collection was successful in 79.7% (141/177, hypoxemia n = 10; gestational age ≤ 30 weeks n = 54; IUGR n = 71; TTTS n = 6). The median blood loss in cases with attempted but failed collection of UCB was 1,400 ml (range: 500–1,800 ml). The median blood loss in cases with successful collection of UCB was 500 ml (range: 250–2,500 ml).

Quantity and Quality of Obtained UCB

In 141 cases with successfully collected UCB, 105 units had sufficient quality and quantity for potential therapy. A total of 36 UCB units lacked sufficient quantity and/or quality for potential therapy. Eight units of UCB (8/141, 5.7%) were microbiologically contaminated. In 28 units the cell amount or quality was insufficient for potential cell therapy due to an insufficient cell count for at least one dose of the target dose (1–5 × 10^7 cells/kg) at birthweight and/or cell viability < 75% (for details, see Fig. 1). Almost all of these cases (82.1%, 23/28) were preterm infants with a gestational age of less than 30 weeks or birthweight of less than 1,500 g. Five cases (1.8%, 5/28) were neonates with IUGR. Characteristics of cases with collected UCB are summarized in Table 1. Quantity and quality of collected UCB cells appeared to correlate with gestational age: the stored UCB volume and the nuclear cell count were strongly related to gestational age (Rs = 0.66, P < 0.001 and Rs = 0.74, P < 0.001, respectively) (see Fig. 2). Cell viability was only weakly correlated with gestational age (Rs = 0.19, P = 0.04).

Training Effect

In the first 3 months (December to February) of the project, 41 cases were enrolled. Thirty-six percent of these cases were missed (14/41). At this point only obstetricians were trained to collect the UCB and collection kits were stored in a collective place. After February 2018, a systematical training system and logistic changes were implied. Teams of all disciplines involved (obstetricians, neonatologists, midwives, anesthetists, and surgical assistants) received trainings and were informed about the study. Trainings were repeated monthly. Missed cases and incorrectly collected samples were discussed by the research staff during daily ward rounds with midwives and obstetricians in the delivery suite. During an established weekly perinatal conference, where important cases were discussed between obstetricians, midwives, and neonatologists, weekly updates on the progress of the study were given and outcome of patients with collected UCB were discussed. Collection kits were now placed in all delivery areas and operating suites. With these efforts, there was a learning curve within the team (see Fig. 3) and an average of only 8.8% of enrolled cases (12/136) were missed during the rest of the year (March 2018 to December 2018). The positive impact of daily supervision by the research personnel for successful UCB collection is illustrated by a period of 2 weeks in April 2018, where a peak of missed collections can be observed (three cases) while both doctors responsible for the study were not on site for a period of 2 weeks simultaneously.
Outcome of Included Neonates

Six (3.4%) of all included neonates deceased. Four of whom were extreme preterm infants with a gestational age of less than 25 weeks and deceased within days after birth, one was discovered to suffer from a complex congenital heart anomaly and one from a congenital cardiomyopathy. As illustrated in Table 2, 10.7% (19/177) of all included neonates developed brain lesions. The most common events were IVH (9/177, 5%) and HIE (7/177, 4%), followed by PVL (2/177, 1%) and CP (1/177, 0.5%). Within the different groups,
neonates with TTTS had by far the highest prevalence of perinatal brain damage with 80% (4/5), 36.8% (7/19) of children with perinatal hypoxemia suffered from HIE and 11.6% (8/69) of neonates born with a gestational age of \( \leq 30 + 0 \) weeks suffered from IVH \((n = 7)\) or PVL \((n = 1)\). Within the group of neonates with IUGR none (0/82) were affected by perinatal brain damage.

**Discussion**

**Integration of UCB Collection into Routine Proceedings**

The present single-center study assessed the feasibility of UCB collection in neonates at high risk of perinatal brain damage. Our data show that the collection of autologous UCB in neonates at high risk of brain damage is organizationally possible but challenging. Multidisciplinary collaboration, daily team briefings, and personal engagement were essential for the success of the study. Figure 3 illustrates the training effect in the study.

In 82.5% of all cases the collection of UCB was attempted (174/211). In 23 of these cases UCB was collected prophylactically but the inclusion criteria were not met (see Fig. 1) and the UCB was discarded. One hundred and seventy-seven cases fulfilled the inclusion criteria. In 80% of these cases (141/177) the collection was successful. Integrating the collection of UCB into routine proceedings is essential to overcome organizational difficulties of the collection, especially in emergency settings. The collection rate in cases with expected high-risk deliveries was much higher (89.1%, 98/110) than the rate of attempted collections in obstetric emergencies (75.2%, 76/101). Emergencies such as crash C-sections and vacuum extractions complicate the collection of UCB as they challenge the team and may distract from the collection of UCB. 67.6% (25/37) of all missed cases in this study were vacuum extractions and emergency C-sections.

In another study of UCB collection for banking, 16.6% of cases were missed due to dystocial child birth and urgent C-section\(^{32}\). A possible future approach to overcome organizational failures may be the system of “all collect.” To guarantee the collection of UCB in tricky situations, UCB could just be routinely collected after every delivery just like arterial blood-gas analyses are routinely performed from UCB after delivery. Whether an “all collect” system is worth the effort has to be determined in the future depending on chances of actual use of autologous UCB units.

**Impact of Gestational Age on Quality of UCB Cells**

Collection of UCB may not only be challenging for organizational reasons but also for technical reasons: first, a greater loss of maternal blood seems to complicate the collection of UCB. In 10 cases of attempted but failed UCB collection the median maternal blood loss was 1,400 ml (range: 500–1,800 ml). This can be explained through the placenta being spared during maternal centralization of blood circulation. Situations like placental abruption and uterine rupture are therefore not only life threatening for the unborn child and the mother but may also influence the collection of UCB. Second, the gestational age of the affected child appears to be a major issue for the quantity and quality of the collected UCB. Both the stored UCB volume and nuclear cell count correlated with increasing gestational age. In 42.6% \((n = 23/54)\) of UCB units collected from preterm neonates with a gestational age of \( \leq 30 + 0 \) weeks, the sample was insufficient for transplantation either due to a too low amount of TNC for at least one dose containing the target cell number at birthweight or viability of less than 75% of cells. Conversely, almost all cases (23/28) with an insufficient quantity of UCB cells for transplantation were preterm infants.

To date, several studies have shown that the cord blood volume and TNC are positively correlated with birthweight, but none of them have investigated cord blood collection in extreme preterm infants. Clinical trials involving autologous UCB cells mostly involve mature neonates or have included preterm infants with \( 28 + 1 \) to \( 37 + 0 \) weeks of gestation\(^{24,25,27,28,33}\). Ballen et al. noted that each 500 g increase in the infants’ weight caused a 6%, 11%, 22%, and 28% increase in the volume, TNC, colony-forming units, and CD34+ cell concentration, respectively\(^{34}\). In preterm infants UCB volume is additionally lost through late cord clamping, which is a recommended standard operating procedure through several best practice committees, including the ACOG (American College of Obstetricians and Gynecologists) and the AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften)\(^{35}\). Faster cord clamping results in the maintenance of blood flow and collection of a greater blood volume\(^{36,37}\).

**Alternative Cell Sources for Extreme Preterm Infants**

Studies comparing quality and quantity of preterm and term cord blood cells are lacking. An animal model of Huang et al. shows that autologous UCB term and UCB preterm cells are both effective but appear to differ in mechanisms of neuroprotection\(^{38}\). For clinical translation of cell therapies apart from effectiveness, dosing is another major issue. Recent studies have shown that for mature neonates \( \geq 35 \) weeks of gestation autologous cord blood units collected through trained stuff harbor an adequate cell number for planned cellular therapy\(^{24}\). For preterm infants, on the other hand, quantity of collected autologous UCB cells is critical as shown in this study. Therefore, for extremely preterm infants with a gestational age of \( \leq 30 \) weeks or a birthweight of \( \leq 1,500 \) g alternative sources for perinatal cells should be considered. UCB is a rich source of primitive multipotent stem/progenitor cells\(^{39}\) including mesenchymal stromal cells (MSCs). MSCs are a promising cell type with therapeutic potential for neonatal brain disorders and can be harvested not only from UCB but also from umbilical cord Wharton’s jelly or from nonperinatal sources such as bone marrow or adipose tissue\(^{40}\). Beneficial effects of MSC-based therapies
have been demonstrated mainly in animal models of bronchopulmonary dysplasia but lately also in models of IVH, neonatal stroke, and HIE\textsuperscript{41–50}. Current phase 1 clinical trials have shown human UCB-derived MSCs to be safe in the treatment of severe IVH in preterm infants and bronchopulmonary dysplasia\textsuperscript{51–53}. We therefore suggest umbilical cord Wharton’s jelly as another alternative cell source for preterm infants with an insufficient quantity of UCB cells.

**Role of Autologous UCB Application in Comparison to Allogenic Application**

Until today banking of autologous UCB has been organized mostly through private cord blood banks. Current data show that at the time there is only a very low possibility of future use for banked autologous cord blood units collected in the absence of a known indication from a healthy infant\textsuperscript{54,55}. A different approach is targeted collection from high-risk populations that could benefit from autologous cord blood. With 10.7\% (19/177) a high proportion of the included children in this study suffered from perinatal brain damage indicating that targeted collection of UCB in these high-risk populations may be worthwhile. Because none of the children with IUGR suffered from brain lesions, we suggest that this group may be excluded for a more efficient approach in the future. Other neonatological populations that may benefit from autologous cord blood are preterm infants developing bronchopulmonary dysplasia or neonates undergoing surgical correction of congenital cardiac defects\textsuperscript{47,56–59}.

Autologous approaches harbor a favorable risk profile as they minimize the risk of immunogenic reactions and infections, such as graft versus host disease or even undiagnosed infectious agents (e.g., prions). The safety of an innovative treatment is of particular importance in critical patients such as newborn children. Nevertheless, collection of autologous cells is more complicated and the preparation and manufacturing of cells from individual cell sources has to become standardized to design valuable clinical trials for autologous treatment.

Allogenic approaches have a logistic advantage because cells can be manufactured and be used “off the shelf” in the clinical setting\textsuperscript{26}. Furthermore, some UCB cells like MSCs lack MHC II antigens and are therefore immune privileged even in the allogenic setting\textsuperscript{60,61}.

Reliable studies directly comparing efficiency and safety of allogenic and autologous treatment options are lacking. In a small case series with only seven patients with HIE, Bae et al. reported lower levels of proinflammatory cytokines and greater improvement in gross motor performance in intravenous application of allogenic UCB compared with that of autologous UCB\textsuperscript{62}. To date, no larger study has been published. Early phase clinical studies suggest that properly administered autologous UCB is effective in the treatment of brain damage\textsuperscript{63,64,65}.

Overall, autologous UCB units appear to be comparable to allogenic UCB units in quantity and quality of cells. While autologous options appear safer, allogenic options harbor logistic advantages. It has to be determined whether the additional expenditure and logistic challenges related to autologous approaches are reasonable. However, this decision should not depend on the effort but on efficiency of treatment.

**Limitations of the Study**

We classified cases to have an insufficient quality of cells if the contained number of cells was too low for at least one treatment with the target dose at birthweight (minimum 1–5 \times 10^7 \text{cells/kg}). The target dose was based on the dose range presently used in allogeneic transplant after myeloablative chemotherapy. However, the effective dose in the autologous setting and for the treatment of brain lesions is not known and could be lower or higher. If UCB is transplanted at a later age, higher doses may be needed to be beneficial for a higher weight. The optimal dose and optimal timing for cell transplantation remain to be defined. Therefore, the clinical translation of the collected data is complex and the number of cases with sufficient quantity and quality of cells could vary from our current calculations.

The collected volume of UCB units varied widely. These differences can be explained through the variety of gestational ages and birthweights. However, UCB has been collected by different obstetricians and midwives, and the impact of individual sampling techniques was not monitored. In the future, standardized sets with a specified vacuum instead of using gravity could be developed and used to make UCB collection more comparable and possibly improve generated volumes.

**Conclusion**

Our data show that the autologous collection of UCB in neonates at high risk of brain damage is possible through extensive multidisciplinary collaboration required among neonatologists, the labor and delivery ward, and the cord blood bank. In the aforementioned high-risk population, the prevalence of brain damage is high with 10.7\% (19/177) and may justify the effort made to obtain autologous cells from UCB or other perinatal sources from these children. The nuclear cell count and stored UCB volume correlated strongly with gestational age ($P < 0.001$), and the targeted dose was often not reached in very preterm infants. We therefore suggest that for preterm infants with a gestational age \leq 30 + 0 weeks, umbilical cord MSCs should be investigated as an alternative cell source to UCB.

**Acknowledgments**

This study was supported by research grant from the Vita 34 AG, a cord blood bank, without which this work could not have been done. We are especially grateful to Dr Thomas Böse, Dr Josefina Zschaler, and Dr Susan Hetz for their advice and assistance. Moreover, we are grateful that Vita 34 AG offered banking of the obtained UCB units free of charge for 18 years for the included cases.
patients and their families. We thank all midwives, nurses, and the administrative staff for their work on behalf of this study. We are indebted to the patients and families for their commitment to participating in this trial.

Authors’ Contributions
AS: Manuscript writing, conception and design of the study, collection and assembly of data, information of patients, data analysis, and interpretation; TB: Administrative support, conception and design of the study, data analysis and interpretation, review of the manuscript, and final approval of manuscript; HSF: Administrative support, data analysis and interpretation, review of the manuscript, and final approval of manuscript; RD: Collection and assembly of data, information of patients, review of the manuscript, and final approval of manuscript; C-RW: Collection and assembly of data, information of patients, review of the manuscript, and final approval of manuscript; AS: Collection and assembly of data, information of patients, review of the manuscript, and final approval of manuscript; CJ: Administrative support, data analysis and interpretation, review of the manuscript, and final approval of manuscript; CB: Administrative support, conception and design of the study, provision of follow-up data, review of the manuscript, and final approval of manuscript; and WH: Conception and design of the study, review of the manuscript, and final approval of manuscript.

Data Availability Statement
The authors confirm that the data supporting the findings of this study are available within the article. Raw data were generated at Charité University Hospital Berlin. Additional data supporting the findings of this study are available from the corresponding author AS on request.

Ethical Approval
This study was approved by the Institutional Ethics Committee of the Charité – Universitätsmedizin Berlin, Berlin, Germany (EA2/206/17).

Statement of Human and Animal Rights
The use of human umbilical cord blood and all procedures in this study were conducted in accordance with the Institutional Ethics Committee of the Charité – Universitätsmedizin Berlin (Berlin, Germany) (EA2/206/17) approved protocols.

Statement of Informed Consent
Written informed consent was obtained from the patients for their anonymized information to be published in this article.

Declaration of Conflicting Interests
The authors report funding from the Vita 34 AG, Leipzig, in form of financing a full-time position for a physician for 2 years. This position was filled by AS. The other authors indicated no potential conflicts of interest. The Vita 34 AG performed the transport and preparation of the obtained UCB free of charge. All collected data and results of this study were intellectual property of the authors and not the Vita 34 AG and the authors alone bear the responsibility for data analysis and interpretation. The corresponding author has the permission of the other authors to submit the manuscript.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Vita 34 AG, Leipzig, Germany, in form of financing a full-term position for one physician for 2 years.

ORCID iD
Angela Segler 🐦 https://orcid.org/0000-0001-9507-9150

References
1. Babcock MA, Kostova FV, Ferriero DM, Johnston MV, Brunstrom JE, Hagberg H, Maria BL. Injury to the preterm brain and cerebral palsy: clinical aspects, molecular mechanisms, unanswered questions, and future research directions. J Child Neurol. 2009;24(9):1064–1084.
2. Fatemi A, Wilson MA, Johnston MV. Hypoxic-ischemic encephalopathy in the term infant. Clin Perinatol. 2009;36(4):835–858, vii.
3. Petrou S, Mehta Z, Hockley C, Cook-Mozaffari P, Henderson J, Goldacre M. The impact of preterm birth on hospital inpatient admissions and costs during the first 5 years of life. Pediatrics. 2003;112(6 Pt 1):1290–1297.
4. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptok AR, Walsh MC, Hale EC, Newman NS, Schibler K, Carlo WA, Kennedy KA, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010;126(3):443–456.
5. Johnston MV, Hoon AH Jr. Cerebral palsy. Neuromolecular Med. 2006;8(4):435–450.
6. Habli M, Lim FY, Crombleholme T. Twin-to-twin transfusion syndrome: a comprehensive update. Clin Perinatol. 2009; 36(2):391–416, x.
7. Broxmeyer HE, Douglas GW, Hangoc G, Cooper S, Bard J, English D, Arny M, Thomas L, Boyse EA. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A. 1989; 86(10):3828–3832.
8. Broxmeyer HE, Srouf EF, Hangoc G, Cooper S, Anderson SA, Bodine DM. High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci U S A 2003;100(2):645–650.
9. Liao Y, Cotten M, Tan S, Kurtzberg J, Cairo MS. Rescuing the neonatal brain from hypoxic injury with autologous cord blood. Bone Marrow Transplant. 2013;48(7):890–900.
10. Liao Y, Geyer MB, Yang AJ, Cairo MS. Cord blood transplantation and stem cell regenerative potential. Exp Hematol. 2011; 39(4):393–412.
11. Oppliger B, Joerger-Messerli M, Mueller M, Reinhart U, Schneider P, Surbek DV, Schoeberlein A. Intranasal delivery of umbilical cord-derived mesenchymal stem cells preserves myelination in perinatal brain damage. Stem Cells Dev. 2016; 25(16):1234–1242.
12. Pimentel-Coelho PM, Magalhaes ES, Lopes LM, deAzevedo LC, Santiago MF, Mendez-Otero R. Human cord blood transplantation in a neonatal rat model of hypoxic-ischemic brain
damage: functional outcome related to neuroprotection in the striatum. Stem Cells Dev. 2010;19(3):351–358.

13. Pimentel-Coelho PM, Mendez-Otero R. Cell therapy for neonatal hypoxic-ischemic encephalopathy. Stem Cells Dev. 2010;19(3):299–310.

14. Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, Tsukamoto Y, Iso H, Fujimori Y, Stem DM, Naritomi H, et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest. 2004;114(3):330–338.

15. Vendrame M, Gemma C, de Mesquita D, Collier L, Bickford PC, Sanberg CD, Sanberg PR, Pennypacker KR, Willing AE. Anti-inflammatory effects of human cord blood cells in a rat model of stroke. Stem Cells Dev. 2005;14(5):595–604.

16. Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, Sanchez-Ramos J, Chopp M. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001;32(11):2682–2688.

17. Drobyshhevsky A, Cotten CM, Shi Z, Luo K, Jiang R, Derrick M, Tracy ET, Gentry T, Goldberg RN, Kurtzberg J, Tan S. Human umbilical cord blood cells ameliorate motor deficits in rabbits in a cerebral palsy model. Dev Neurosci. 2015; 37(4–5):349–362.

18. Lu D, Sanberg PR, Mahmood A, Li Y, Wang L, Sanchez-Ramos J, Chopp M. Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. Cell Transplant. 2002;11(3):275–281.

19. Meier C, Middelans J, Wasielewski B, Neuhoff S, Roth-Haerer A, Gantert M, Dinse HR, Dermietzel R, Jensen A. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res. 2006; 59(2):244–249.

20. Nan Z, Grande A, Sanberg CD, Sanberg PR, Low WC. Infusion of human umbilical cord blood ameliorates neurologic deficits in rats with hemorrhagic brain injury. Ann N Y Acad Sci. 2005;1049:84–96.

21. Nishio Y, Koda M, Kamada T, Someya Y, Yoshinaka K, Okada S, Harada H, Okawa A, Moriya H, Yamazaki M. The use of hemopoietic stem cells derived from human umbilical cord blood to promote restoration of spinal cord tissue and recovery of hindlimb function in adult rats. J Neurosurg Spine. 2006;5(5):424–433.

22. Vendrame M, Cassady J, Newcomb J, Butler T, Pennypacker KR, Zigova T, Sanberg CD, Sanberg PR, Willing AE. Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. Stroke. 2004;35(10):2390–2395.

23. Zhao ZM, Li HJ, Liu HY, Lu SH, Yang RC, Zhang QJ, Han ZC. Intraspinal transplantation of CD34+ human umbilical cord blood cells after spinal cord hemisection injury improves functional recovery in adult rats. Cell Transplant. 2004;13(2):113–122.

24. Cotten CM, Murtha AP, Goldberg RN, Grotegut CA, Smith PB, Goldstein RF, Fisher KA, Gustafson KE, Waters-Pick B, Swamy GK, Rattray B, et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr. 2014;164(5):973–979.e971.

25. Sun JM, Kurtzberg J. Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism. Pediatr Res. 2018;83(1–2):364–371.

26. Ahn SY, Chang YS, Park WS. Stem cells for neonatal brain disorders. Neonatology 2016;109(4):377–383.

27. Carpenter KHL, Major S, Tallman C, Chen LW, Franz L, Sun J, Kurtzberg J, Song A, Dawson G. White matter tract changes associated with clinical improvement in an open-label trial assessing autologous umbilical cord blood for treatment of young children with autism. Stem Cells Transl Med. 2019; 8(2):138–147.

28. Yang J, Ren Z, Zhang C, Rao Y, Zhong J, Wang Z, Liu Z, Wei W, Wu L, Wen J, Liu G, et al. Safety of autologous cord blood cells for preterm: a descriptive study. Stem Cells Int. 2018; 2018:5268057.

29. Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, Dan B, Jacobsson B. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8–14.

30. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92(4):529–534.

31. de Vries LS, Eken P, Dubowitz LM. The spectrum of leukomalacia using cranial ultrasound. Behav Brain Res. 1992; 49(1):1–6.

32. Valle V, Serenci M, Murgi E, Capozzi M, Girelli G. Collection of umbilical cord blood for banking: collection rate and factors influencing collection. Blood Transfus 2017; 15(6):587–588.

33. van den Broek BTA, Page K, Paviglianiti A, Hol J, Allevelt H, Volt F, Michel G, Diaz MA, Bordon V, O’Brien T, Shaw PJ, et al. Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Adv. 2018;2(1):49–60.

34. Ballen KK, Wilson M, Wuu J, Ceredena AM, Hsieh C, Stewart FM, Popovsky MA, Quesenberry PJ. Bigger is better: maternal and neonatal predictors of hematopoietic potential of umbilical cord blood units. Bone Marrow Transplant. 2001;27(1):7–14.

35. Committee on Obstetric P. Committee Opinion No. 684: delayed umbilical cord clamping after birth. Obstet Gynecol. 2017;129(1):e5–e10.

36. Santos SV, Barros SM, Santos MS, Marti LC, Ribeiro AA, Damiano D, Dan B, Jacobsson B. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8–14.

37. Valle V, Serenci M, Murgi E, Capozzi M, Girelli G. Collection of umbilical cord blood for banking: collection rate and factors influencing collection. Blood Transfus 2017; 15(6):587–588.

38. van den Broek BTA, Page K, Paviglianiti A, Hol J, Allevelt H, Volt F, Michel G, Diaz MA, Bordon V, O’Brien T, Shaw PJ, et al. Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Adv. 2018;2(1):49–60.

39. Ballen KK, Wilson M, Wuu J, Ceredena AM, Hsieh C, Stewart FM, Popovsky MA, Quesenberry PJ. Bigger is better: maternal and neonatal predictors of hematopoietic potential of umbilical cord blood units. Bone Marrow Transplant. 2001;27(1):7–14.

40. Committee on Obstetric P. Committee Opinion No. 684: delayed umbilical cord clamping after birth. Obstet Gynecol. 2017;129(1):e5–e10.

41. Santos SV, Barros SM, Santos MS, Marti LC, Ribeiro AA, Damiano D, Dan B, Jacobsson B. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8–14.
39. Mayani H, Alvarado-Moreno JA, Flores-Guzman P. Biology of human hematopoietic stem and progenitor cells present in circulation. Arch Med Res. 2003;34(6):476–488.
40. Kobolak J, Dinnyes A, Memic A, Khademhosseini A, Mobasher A. Mesenchymal stem cells: identification, phenotypic characterization, biological properties and potential for regenerative medicine through biomaterial micro-engineering of their niche. Methods. 2016;99:62–68.
41. Ahn SY, Chang YS, Sung DK, Sung SI, Yoo HS, Im GH, Choi SJ, Park WS. Optimal route for mesenchymal stem cells transplantation after severe intraventricular hemorrhage in newborn rats. PLoS One. 2015;10(7):e0132919.
42. Ahn SY, Chang YS, Sung DK, Sung SI, Yoo HS, Lee JH, Oh WI, Park WS. Mesenchymal stem cells prevent hydrocephalus after severe intraventricular hemorrhage. Stroke. 2013;44(2):497–504.
43. Donega V, Nijboer CH, van Velthoven CT, Youssef SA, de Bruin A, van Bel F, Kavelaars A, Heijnen C J. Assessment of long-term safety and efficacy of intranasal mesenchymal stem cell treatment for neonatal brain injury in the mouse. Pediatr Res. 2015;78(5):520–526.
44. Donega V, van Velthoven CT, Nijboer CH, van Bel F, Kas MJ, Kavelaars A, Heijnen CJ. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. PLoS One. 2013;8(1):e51253.
45. Kim ES, Ahn SY, Im GH, Sung DK, Park YR, Choi SH, Choi SJ, Chang YS, Oh W, Lee JH, Park WS. Human umbilical cord blood-derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats. Pediatr Res. 2012;72(3):277–284.
46. Kim YE, Sung SI, Chang YS, Ahn SY, Sung DK, Park WS. Thrombin preconditioning enhances therapeutic efficacy of human Wharton’s jelly-derived mesenchymal stem cells in severe neonatal hypoxic ischemic encephalopathy. Int J Mol Sci. 2019;20(10):2477.
47. Mobius MA, Rudiger M. Mesenchymal stromal cells in the development and therapy of bronchopulmonary dysplasia. Mol Cell Pediatr. 2016;3(1):18.
48. Mueller M, Oppliger B, Joerger-Messerli M, Reinhart U, Barnea E, Paidas M, Kramer BW, Surbek DV, Schoeberlein A. Wharton’s jelly mesenchymal stem cells protect the immature brain in rats and modulate cell fate. Stem Cells Dev. 2017;26(4):239–248.
49. Park WS, Sung SI, Ahn SY, Yoo HS, Sung DK, Im GH, Choi SJ, Chang YS. Hypothemia augments neuroprotective activity of mesenchymal stem cells for neonatal hypoxic-ischemic encephalopathy. PLoS One. 2015;10(3):e0120893.
50. Vaes JEG, Vink MA, de Theije CGM, Hoebeek FE, Benders M, Nijboer CH A. The Potential of stem cell therapy to repair white matter injury in preterm infants: lessons learned from experimental models. Front Physiol. 2019;10:540.
51. Ahn SY, Chang YS, Kim JH, Sung SI, Park WS. Two-Year Follow-up outcomes of premature infants enrolled in the phase i trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr. 2017;185:49–54.e42.
52. Ahn SY, Chang YS, Sung SI, Park WS. Mesenchymal stem cells for severe intraventricular hemorrhage in preterm infants: phase i dose-escalation clinical trial. Stem Cells Transl Med. 2018;7(12):847–856.
53. Chang YS, Ahn SY, Yoo HS, Sung SI, Choi SJ, Oh WI, Park WS. Mesenchymal stem cells for bronchopulmonary dysplasia: phase i dose-escalation clinical trial. J Pediatr. 2014;164(5):966–972.e966.
54. Hollands P, McCauley C. Private cord blood banking: current use and clinical future. Stem Cell Rev Rep. 2009;5(3):195–203.
55. Thornley I, Eapen M, Sung L, Lee SJ, Davies SM, Joffe S. Private cord blood banking: experiences and views of pediatric hematopoietic cell transplantation physicians. Pediatrics. 2009;123(3):1011–1017.
56. Chasovskyi K, Fedeych v O, McMullan DM, Mykych k Y, Vorobiova G, Zhovnir V, Yemets I. Tissue perfusion in neonates undergoing open-heart surgery using autologous umbilical cord blood or donor blood components. Perfusion. 2015;30(6):499–506.
57. Fedeych v O, Chasovskyi K, Vorobiova G, Zhovnir V, Makarenko M, Kurkevych A, Maksymenko A, Yemets I. Open cardiac surgery in the first hours of life using autologous umbilical cord blood. Eur J Cardiothorac Surg. 2011;40(4):985–989.
58. Ren Z, Xu F, Zhang X, Zhang C, Miao J, Xia X, Kang M, Wei W, Ma T, Zhang Q, Lu L, et al. Autologous cord blood cells infusion in preterm neonates safely reduces respiratory support duration and potentially preterm complications. Stem Cells Transl Med. 2020;9(2):169–176. Epub 2019 Nov 8.
59. Sarin K, Chauhan S, Biso i AK, H azarika A, Malhotra N, Manek P. Use of autologous umbilical cord blood transfusion in neonates undergoing surgical correction of congenital cardiac defects: a pilot study. Ann Card Anaesth. 2018;21(3):270–274.
60. De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012;12(5):574–591.
61. Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW. Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol. 2013;91(1):32–39.
62. Bae SH, Lee HS, Kang MS, Strupp BJ, Chopp M, Moon J. The levels of pro-inflammatory factors are significantly decreased in cerebral palsy patients following an allogeneic umbilical cord blood cell transplant. Int J Stem Cells. 2012;5(1):31–38.
63. Englander ZA, Sun J, Laura C, Mikati MA, Kurtzberg J, Song AW. Brain structural connectivity increases concurrent with functional improvement: evidence from diffusion tensor MRI in children with cerebral palsy during therapy. Neuroimage Clin. 2015;7:315–324.